Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares some updated results from the Phase III LACEWING trial (NCT02752035), which compared the use of gilteritinib plus azacitidine versus azacitidine alone in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) ineligible for intensive chemotherapy. Dr Wang comments on the improved overall response rate (ORR) observed in patients receiving gilteritinib plus azacitidine, and further highlights how data from this trial may impact future studies in the field. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.